Close Close

Financial Planning > UHNW Client Services > Family Office News

Gilead’s India patent snag may spur more low-cost Sovaldi copies

Your article was successfully shared with the contacts you provided.

(Bloomberg) –The Indian patent office’s rejection of a key patent for Gilead Sciences Inc.’s Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country, potentially aiding local companies including Natco Pharma Ltd.

The New Delhi patent office this week rejected the main patent claim for Sovaldi on grounds that it “lacks novelty” and lacks an inventive step. Sovaldi’s $84,000 pricetag for a 12-week course in the U.S. has drawn criticism from patient advocates.

See also: Biotech investors bail out after Gilead’s drug pricing fight.

Drugmakers including Pfizer Inc., Novartis A.G. and Roche Holding A.G. have seen patent applications for blockbuster drugs rejected in India because of stricter standards for innovation. India’s government also caps many drug prices to ensure that the country’s poorest can afford them.

A potential beneficiary of the patent office’s decision on Sovaldi is Hyderabad,India-based Natco, which is opposing the grant of another patent on the formulation of Sovaldi in India. Rajeev Nannapaneni, chief executive officer of Natco, declined to comment.

A Gilead representative couldn’t immediately be reached for comment outside of regular business hours in the U.S. Gilead said in its response to the patent office’s objections that it had been granted patents for similar claims in 17 countries including Israel, China and Indonesia.

While the product could be a big one for Natco, the company will face challenges beating other companies to the market, and reaching patients in rural India, said Nimish Mehta, director of Research Delta Advisors. Competing with Natco will be seven other Indian drugmakers — Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. — who were awarded licenses by Gilead in September to manufacture copies of the drug for 91 countries that are mainly low-income regions. India has 12 million people infected with hepatitis C.

Gilead plans to sell its branded version of Sovaldi in India at a cost of $900 for 12 weeks of therapy, Gregg Alton, an executive vice president at the Foster City, California-based company, said in September.

Chaitanya Prasad, controller general of patents, designs and trademarks, didn’t immediately return a call to his office seeking comment.

Gilead’s Sovaldi changed hepatitis C treatment when it was approved in 2013. Previous therapies relied on shots given weekly for a year and cured only about half of patients with the most common U.S. strain, called genotype 1. The drugs also caused side effects that include fatigue and flu-like symptoms. Sovaldi is a pill taken once a day, with fewer side effects, though patients can still get fatigue, headache and nausea.

See also: Cost to develop a drug more than doubles.